214 related articles for article (PubMed ID: 26577828)
1. Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.
Kim H; Youk J; Yang Y; Kim TY; Min A; Ham HS; Cho S; Lee KH; Keam B; Han SW; Oh DY; Ryu HS; Han W; Park IA; Kim TY; Noh DY; Im SA
J Cancer Res Clin Oncol; 2016 Mar; 142(3):707-14. PubMed ID: 26577828
[TBL] [Abstract][Full Text] [Related]
2. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
White R; Dinneen T; Makris A
Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.
Yang Y; Im SA; Keam B; Lee KH; Kim TY; Suh KJ; Ryu HS; Moon HG; Han SW; Oh DY; Han W; Kim TY; Park IA; Noh DY
BMC Cancer; 2016 Jul; 16():515. PubMed ID: 27444430
[TBL] [Abstract][Full Text] [Related]
6. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer.
Toi M; Taniguchi T; Ueno T; Asano M; Funata N; Sekiguchi K; Iwanari H; Tominaga T
Clin Cancer Res; 1998 Mar; 4(3):659-64. PubMed ID: 9533534
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Nov; 7():203. PubMed ID: 17976237
[TBL] [Abstract][Full Text] [Related]
8. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.
Keam B; Im SA; Lim Y; Han SW; Moon HG; Oh DY; Cho N; Lee SH; Han W; Moon WK; Kim DW; Kim TY; Park IA; Noh DY
Ann Surg Oncol; 2013 Jul; 20(7):2242-9. PubMed ID: 23529780
[TBL] [Abstract][Full Text] [Related]
12. Circulating HOTAIR expression predicts the clinical response to neoadjuvant chemotherapy in patients with breast cancer.
Lu R; Zhang J; Zhang W; Huang Y; Wang N; Zhang Q; Qu S
Cancer Biomark; 2018; 22(2):249-256. PubMed ID: 29630518
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of hepatocyte growth factor in breast cancer patients.
Taniguchi T; Toi M; Inada K; Imazawa T; Yamamoto Y; Tominaga T
Clin Cancer Res; 1995 Sep; 1(9):1031-4. PubMed ID: 9816076
[TBL] [Abstract][Full Text] [Related]
14. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.
Carey LA; Metzger R; Dees EC; Collichio F; Sartor CI; Ollila DW; Klauber-DeMore N; Halle J; Sawyer L; Moore DT; Graham ML
J Natl Cancer Inst; 2005 Aug; 97(15):1137-42. PubMed ID: 16077072
[TBL] [Abstract][Full Text] [Related]
15. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Matsuda N; Hayashi N; Ohde S; Yagata H; Kajiura Y; Yoshida A; Suzuki K; Nakamura S; Tsunoda H; Yamauchi H
J Surg Oncol; 2014 Jun; 109(8):764-9. PubMed ID: 24647874
[TBL] [Abstract][Full Text] [Related]
16. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
17. Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
Kai K; Arima N; Miyayama H; Yamamoto Y; Iwase H; Nishimura R
Breast Cancer; 2009; 16(1):42-8. PubMed ID: 18504642
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy in stage III breast cancer.
Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of hepatocyte growth factor in patients with breast cancer.
Sheen-Chen SM; Liu YW; Eng HL; Chou FF
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]